BioLineRx (BLRX) investor relations material

Executive summary

• First patient dosed in phase I/IIa trial of GLIX1 for glioblastoma at NYU Langone Health in March 2026, with additional leading cancer centers participating and further sites to open soon.

• GLIX1 targets DNA damage repair by restoring TET2 activity, showing robust preclinical efficacy in GBM models, including temozolomide-resistant cases; new data presented at ASCO 2026 highlighted its novel mechanism and safety profile.

• APHEXDA sales rose to $2.7 million in Q1 2026 from $1.4 million in Q1 2025, generating $0.5 million in royalty revenue.

• Motixafortide development in pancreatic cancer (PDAC) continues, with the CheMo4METPANC phase IIb trial enrolling well and interim futility analysis expected later in 2026.

• No new equity raised in Q1 2026; cash position supported by prior financings, with loan repayments and lease liabilities ongoing.

Financial highlights

• Q1 2026 revenues were $0.5 million, up from $0.3 million year-over-year, driven by increased APHEXDA royalties.

• Research and development expenses rose to $2.5 million from $1.6 million, mainly due to GLIX1 project costs.

• General and administrative expenses decreased to $0.9 million from $1 million, primarily due to lower legal and other G&A expenses.

• Net non-operating income was $0.5 million, down from $7.6 million, reflecting lower non-cash fair value adjustments of warrant liabilities.

• Net loss for Q1 2026 was $2.6 million, compared to net income of $5.1 million in Q1 2025.

• Cash and equivalents at quarter-end were $17.4 million, sufficient to fund operations into the first half of 2027.

Outlook and guidance

• Periodic updates on the GLIX1 trial expected in the second half of 2026, with full dose escalation results in 2027.

• CheMo4METPANC interim futility analysis anticipated later in 2026; future development strategy will depend on evolving PDAC treatment landscape.

• Cash runway is expected to extend into the first half of 2027.